Comparison of Protectivity and Safety of Two Vaccines against Actinobacillus pleuropneumoniae in a Field Study

Peter Hölzen, Tobias Warnck, Steffen Hoy, Kathleen Schlegel, Isabel Hennig-Pauka and Horst Gaumann
Additional contact information
Peter Hölzen: Vet-Team GmbH, Bokerner Damm 39, 49377 Vechta, Germany
Tobias Warnck: Department of Animal Breeding and Genetics, Justus-Liebig-Universität Gießen, Ludwigstraße 23, 35390 Gießen, Germany
Steffen Hoy: Department of Animal Breeding and Genetics, Justus-Liebig-Universität Gießen, Ludwigstraße 23, 35390 Gießen, Germany
Kathleen Schlegel: Hochschule Anhalt—Anhalt University of Applied Sciences, Strenzfelder Allee 28, 06406 Bernburg (Saale), Germany
Isabel Hennig-Pauka: Field Station for Epidemiology, University of Veterinary Medicine Hannover, Foundation, 49456 Bakum, Germany
Horst Gaumann: Vet-Team GmbH, Bokerner Damm 39, 49377 Vechta, Germany

Agriculture, 2021, vol. 11, issue 11, 1-11

Abstract: Actinobacillus pleuropneumoniae causing porcine pleuropneumoniae is responsible for lowered productivity and reduction of performance indicators such as daily weight gain and increase of losses in the swine industry worldwide. To control the disease, vaccination is used to reduce clinical signs and production losses. A randomized, blinded field trail was conducted to compare two licensed A. pleuropneumoniae vaccines in 600 finishing pigs in terms of lung lesions, mortality, medication, weight gain and safety, in a farm in northeast Germany. After weaning, pigs were allocated randomly in two groups resulting in group sizes of 300 individuals. Nursery pigs were vaccinated at the age of 7 to 10 weeks either with a A. pleuropneumoniae bacterin, containing ApxI-III toxoids (group 1), or with a subunit purified A. pleuropneumoniae toxoid vaccine (group 2). Blinded lung lesion scoring at slaughter following the Ceva Lung Program methodology revealed a significantly lower proportion of lungs affected with pleurisy in group 1 compared to group 2. Weighing of the animals did not show a significant difference ( p = 0.092); however, at the end of finishing animals of group 1 showed a 1.59 kg higher weight (100.40 ± 10.15 kg) compared to animals in group 2 (98.81 kg ± 11.56 kg). Mortality and antimicrobial medication were significantly lower in group 1 compared to group 2 (13 losses and 17 antimicrobial medications in group 2, 4 losses and 1 antimicrobial medications in group 1). Injection site and systemic adverse reactions were recorded on both days of vaccination and did not differ significantly between the groups ( p > 0.05). In this study, the efficacy of vaccination with a commercially available A. pleuropneumoniae bacterin containing ApxI-III toxoids was superior to that of a commercially available A. pleuropneumoniae subunit toxoid vaccine in preventing pulmonary lesions associated with A. pleuropneumoniae infection.Grzegorz Woźniakowski

Keywords: Actinobacillus pleuropneumoniae; porcine pleuropneumoniae; PP; Coglapix; Apx; LPS; vaccination (search for similar items in EconPapers)
JEL-codes: Q1 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2077-0472/11/11/1143/pdf (application/pdf)
https://www.mdpi.com/2077-0472/11/11/1143/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jagris:v:11:y:2021:i:11:p:1143-:d:679154

Access Statistics for this article

Agriculture is currently edited by Ms. Leda Xuan

More articles in Agriculture from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().